An RCT of metformin versus orlistat for the management of obese anovulatory women
Open Access
- 18 December 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 24 (4) , 966-975
Abstract
Treatment of obesity-related anovulation poses a significant clinical challenge. Occasionally, the use of antiobesity medications such as orlistat or insulin sensitizing agents such as metformin is sometimes indicated in these patients. This study aimed to compare the effects of metformin and orlistat for improving ovulation in obese anovulatory women. This was an open-label RCT. A total of 40 women were randomized to receive either metformin (n = 20) or orlistat (n = 20). BMI as well as the androgen profile and the ovulatory status were assessed at baseline and at four weekly intervals for 3 months. Different anthropometric and endocrine parameters were also assessed as possible predictors of ovulation. There was no significant difference between the two study arms regarding the ovulation rate for metformin and orlistat [40% (n = 8/20) and 25% (n = 5/20), respectively, P = 0.31]. Both arms showed a significant drop in the BMI, testosterone and androstendione concentrations (P < 0.05), but there was no difference between the two arms. Patients who ovulated had significantly lower concentrations of baseline LH, androstendione, dehydroepiandrosterone and free androgen index (P < 0.05). Among these factors, a low baseline LH was found to be the only independent predictor of ovulation (area under curve, 0.85). Both metformin and orlistat show a similar effect on weight loss, ovulation rates and androgen concentrations. However, the effects on ovulation rates need to be confirmed in larger studies. The presence of a low baseline serum LH was found to be the most important predictor of ovulation.The study was registered at clinicaltrials.gov. NCT00292799.Keywords
This publication has 52 references indexed in Scilit:
- Why does ovarian surgery in PCOS help? Insight into the endocrine implications of ovarian surgery for ovulation induction in polycystic ovary syndromeHuman Reproduction Update, 2007
- Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetesDiabetes/Metabolism Research and Reviews, 2006
- Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trialBMJ, 2006
- Safety profile of orlistat: results of a prescription-event monitoring studyInternational Journal of Obesity, 2006
- Metformin as Treatment for Overweight and Obese Adults: A Systematic ReviewThe Annals of Family Medicine, 2005
- Metformin Causes Reduction of Food Intake and Body Weight Gain and Improvement of Glucose Intolerance in Combination with Dipeptidyl Peptidase IV Inhibitor in Zucker fa/fa RatsThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndromeThe Journal of Pediatrics, 2004
- Metformin for the treatment of polycystic ovary syndromeObstetrics & Gynecology, 2003
- Clinical, Metabolic and Endocrine Parameters in Response to Metformin in Obese Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind and Placebo-Controlled TrialHormone and Metabolic Research, 2003
- Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndromeGynecological Endocrinology, 2002